Nakagawa K - Search Results

1

Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L.

Uemura T, Kenmotsu H, Hazama D, Teraoka S, Kobe H, Azuma K, Yamaguchi T, Masuda T, Yokoyama T, Otsubo K, Haratani K, Hayakawa D, Oki M, Takemoto S, Ozaki T, Akashi Y, Hata A, Hashimoto H, Yamamoto N, Nakagawa K. Uemura T, et al. Among authors: nakagawa k. Cancer Med. 2023 Dec;12(23):21097-21110. doi: 10.1002/cam4.6668. Epub 2023 Nov 10. Cancer Med. 2023. PMID: 37948122 Free PMC article.

2

Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer.

Yamamoto N, Nishimura Y, Nakagawa K, Matsui K, Fukuoka M. Yamamoto N, et al. Among authors: nakagawa k. Cancer Chemother Pharmacol. 2006 Sep;58(3):285-91. doi: 10.1007/s00280-005-0176-3. Epub 2006 Jan 17. Cancer Chemother Pharmacol. 2006. PMID: 16416334 Clinical Trial.

3

Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104.

Yamamoto N, Nakagawa K, Uejima H, Sugiura T, Takada Y, Negoro S, Matsui K, Kashii T, Takada M, Nakanishi Y, Kato T, Fukuoka M; West Japan Thoracic Oncology Group (WJTOG). Yamamoto N, et al. Among authors: nakagawa k. Cancer. 2006 Aug 1;107(3):599-605. doi: 10.1002/cncr.22024. Cancer. 2006. PMID: 16804877 Free article. Clinical Trial.

4

Phase I and pharmacokinetic study of combination chemotherapy using irinotecan and paclitaxel in patients with lung cancer.

Asai G, Yamamoto N, Kurata T, Tamura K, Uejima H, Nakagawa K, Fukuoka M. Asai G, et al. Among authors: nakagawa k. J Thorac Oncol. 2006 Mar;1(3):226-30. doi: 10.1016/s1556-0864(15)31572-0. J Thorac Oncol. 2006. PMID: 17409861 Free article. Clinical Trial.

5

Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience.

Shimizu T, Satoh T, Tamura K, Ozaki T, Okamoto I, Fukuoka M, Nakagawa K. Shimizu T, et al. Among authors: nakagawa k. Int J Clin Oncol. 2007 Jun;12(3):218-23. doi: 10.1007/s10147-007-0658-x. Epub 2007 Jun 27. Int J Clin Oncol. 2007. PMID: 17566846

6

A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.

Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, Nishio K, Saijo N, Fukuoka M. Kiura K, et al. Among authors: nakagawa k. J Thorac Oncol. 2008 Apr;3(4):386-93. doi: 10.1097/JTO.0b013e318168d228. J Thorac Oncol. 2008. PMID: 18379357 Free article. Clinical Trial.

7

Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer.

Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, Adachi S, Nambu Y, Fujimoto T, Nishiwaki Y, Saijo N, Fukuoka M. Ohe Y, et al. Among authors: nakagawa k. Clin Cancer Res. 2008 Jul 1;14(13):4206-12. doi: 10.1158/1078-0432.CCR-07-5143. Clin Cancer Res. 2008. PMID: 18594001 Clinical Trial.

8

A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.

Yamamoto N, Sekine I, Nakagawa K, Takada M, Fukuoka M, Tanigawara Y, Saijo N. Yamamoto N, et al. Among authors: nakagawa k. Jpn J Clin Oncol. 2009 Jul;39(7):425-30. doi: 10.1093/jjco/hyp038. Epub 2009 Apr 24. Jpn J Clin Oncol. 2009. PMID: 19395467

9

Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.

Tamura K, Okamoto I, Ozaki T, Kashii T, Takeda K, Kobayashi M, Matsui K, Shibata T, Kurata T, Nakagawa K, Fukuoka M. Tamura K, et al. Among authors: nakagawa k. Eur J Cancer. 2009 Aug;45(12):2132-7. doi: 10.1016/j.ejca.2009.04.003. Epub 2009 May 4. Eur J Cancer. 2009. PMID: 19409773 Clinical Trial.

10

Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors.

Shimizu T, Okamoto I, Tamura K, Satoh T, Miyazaki M, Akashi Y, Ozaki T, Fukuoka M, Nakagawa K. Shimizu T, et al. Among authors: nakagawa k. Cancer Chemother Pharmacol. 2010 Jan;65(2):243-50. doi: 10.1007/s00280-009-1028-3. Cancer Chemother Pharmacol. 2010. PMID: 19479254 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,717 results

Search Page